239 related articles for article (PubMed ID: 18416915)
1. Can cheap generic statins achieve national cholesterol lowering targets?
Petty D; Lloyd D
J Health Serv Res Policy; 2008 Apr; 13(2):99-102. PubMed ID: 18416915
[TBL] [Abstract][Full Text] [Related]
2. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Tran YB; Frial T; Miller PS
Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Strony J; Hoffman R; Hanson M; Veltri E
Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trials and recent patterns in the use of statins.
Wang TJ; Stafford RS; Ausiello JC; Chaisson CE
Am Heart J; 2001 Jun; 141(6):957-63. PubMed ID: 11376310
[TBL] [Abstract][Full Text] [Related]
5. Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care.
Hildemann S; Karmann B; Pittrow D; Barho C; Darius H; Bode C
Curr Med Res Opin; 2008 Jun; 24(6):1659-68. PubMed ID: 18457604
[TBL] [Abstract][Full Text] [Related]
6. Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug.
Cheetham TC; Chan J; Benson V; Richmond C; Levin E; Campen D
Am J Manag Care; 2005 Sep; 11(9):546-52. PubMed ID: 16159044
[TBL] [Abstract][Full Text] [Related]
7. Development of indicators for assessing the quality of prescribing of lipid-lowering drugs: data from the pharmacotherapeutic quality circles in Hesse, Germany.
Schubert ; Köster ; Ihle P; von Ferber L
Int J Clin Pharmacol Ther; 2001 Nov; 39(11):492-8. PubMed ID: 11727970
[TBL] [Abstract][Full Text] [Related]
8. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with ezetimibe/simvastatin in a Mediterranean population.
Migdalis I; Efthimiadis A; Pappas S; Alexopoulos D; Vlasserou F; Mikhailidis DP
Curr Med Res Opin; 2009 Oct; 25(10):2571-6. PubMed ID: 19739939
[TBL] [Abstract][Full Text] [Related]
10. Impaired myocardial vasodilatation during hyperaemic stress is improved by simvastatin but not by pravastatin in patients with hypercholesterolaemia.
Yokoyama I; Inoue Y; Moritan T; Ohtomo K; Nagai R
Eur Heart J; 2004 Apr; 25(8):671-9. PubMed ID: 15084372
[TBL] [Abstract][Full Text] [Related]
11. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
[TBL] [Abstract][Full Text] [Related]
12. Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages.
Djaldetti M; Salman H; Bergman M; Bessler H
Exp Mol Pathol; 2006 Apr; 80(2):160-4. PubMed ID: 16269144
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.
Liska B; Khattab AA; Herrmann L; Abdel-Wahab M; Westphal R; Tölg R; Geist V; Richardt G
Herz; 2008 Jul; 33(5):362-7. PubMed ID: 18773156
[TBL] [Abstract][Full Text] [Related]
14. Statin therapy for prevention of coronary artery disease with average cholesterol levels.
Gambhir DS
Indian Heart J; 1999; 51(1):19-20, 105. PubMed ID: 10327772
[No Abstract] [Full Text] [Related]
15. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
Sedjo RL; Cox ER
Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
Hess G; Sanders KN; Hill J; Liu LZ
Am J Manag Care; 2007 Jun; 13 Suppl 3():S80-5. PubMed ID: 17596116
[TBL] [Abstract][Full Text] [Related]
17. LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results.
Heintjes EM; Hirsch MW; van der Linden MW; O'Donnell JC; Stalenhoef AF; Herings RM
Curr Med Res Opin; 2008 Aug; 24(8):2241-50. PubMed ID: 18578957
[TBL] [Abstract][Full Text] [Related]
18. Achieving target cholesterol levels in diabetic patients: potency of the statin or potency of the physician?
Shani M; Dresner J; Vinker S
Isr Med Assoc J; 2008 May; 10(5):354-7. PubMed ID: 18605358
[TBL] [Abstract][Full Text] [Related]
19. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
Ando H; Sugimoto K; Yanagihara H; Tsuruoka S; Saito T; Takamura T; Kaneko S; Fujimura A
Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1012-7. PubMed ID: 18430053
[TBL] [Abstract][Full Text] [Related]
20. Current perspectives on statins.
Mishra TK; Routray S
J Indian Med Assoc; 2003 Jun; 101(6):381-3. PubMed ID: 14579987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
